Acadian Asset Management LLC Sells 222,669 Shares of Aratana Therapeutics, Inc. (NASDAQ:PETX)

Acadian Asset Management LLC reduced its position in shares of Aratana Therapeutics, Inc. (NASDAQ:PETX) by 58.7% during the second quarter, Holdings Channel reports. The institutional investor owned 156,527 shares of the biopharmaceutical company’s stock after selling 222,669 shares during the period. Acadian Asset Management LLC’s holdings in Aratana Therapeutics were worth $1,132,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of PETX. Financial Counselors Inc. purchased a new stake in shares of Aratana Therapeutics during the first quarter worth approximately $101,000. American International Group Inc. raised its stake in shares of Aratana Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 20,534 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 1,354 shares in the last quarter. Ray Gerald L & Associates Ltd. raised its stake in shares of Aratana Therapeutics by 38.2% in the first quarter. Ray Gerald L & Associates Ltd. now owns 23,900 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 6,600 shares in the last quarter. Metropolitan Life Insurance Co. NY raised its stake in shares of Aratana Therapeutics by 17.9% in the first quarter. Metropolitan Life Insurance Co. NY now owns 25,619 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 3,883 shares in the last quarter. Finally, Baird Financial Group Inc. raised its stake in shares of Aratana Therapeutics by 32.0% in the first quarter. Baird Financial Group Inc. now owns 40,758 shares of the biopharmaceutical company’s stock worth $216,000 after buying an additional 9,880 shares in the last quarter. Hedge funds and other institutional investors own 67.85% of the company’s stock.

Shares of Aratana Therapeutics, Inc. (NASDAQ PETX) traded down 0.66% on Thursday, hitting $6.03. The stock had a trading volume of 108,979 shares. Aratana Therapeutics, Inc. has a one year low of $4.97 and a one year high of $10.73. The company’s market cap is $259.30 million. The firm’s 50-day moving average is $7.04 and its 200-day moving average is $6.42.

Aratana Therapeutics (NASDAQ:PETX) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.29) by $0.03. Aratana Therapeutics had a negative return on equity of 51.21% and a negative net margin of 642.93%. The firm had revenue of $5.16 million for the quarter, compared to the consensus estimate of $4.50 million. During the same period in the previous year, the business earned $0.61 earnings per share. The company’s revenue for the quarter was down 86.4% compared to the same quarter last year. On average, analysts expect that Aratana Therapeutics, Inc. will post ($1.04) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Acadian Asset Management LLC Sells 222,669 Shares of Aratana Therapeutics, Inc. (NASDAQ:PETX)” was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/2800549/acadian-asset-management-llc-sells-222669-shares-of-aratana-therapeutics-inc-nasdaqpetx.html.

Several equities research analysts have commented on the company. Jefferies Group LLC restated a “buy” rating and issued a $8.00 price objective on shares of Aratana Therapeutics in a research report on Friday, May 5th. Stifel Nicolaus lowered their price objective on Aratana Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Wednesday, May 10th. Zacks Investment Research upgraded Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $8.00 price objective on the stock in a research report on Tuesday, July 4th. ValuEngine upgraded Aratana Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 25th. Finally, BidaskClub lowered Aratana Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. Aratana Therapeutics has an average rating of “Hold” and an average target price of $10.00.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Want to see what other hedge funds are holding PETX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aratana Therapeutics, Inc. (NASDAQ:PETX).

Institutional Ownership by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.